Iron Overload Clinical Trial
Official title:
A 24-Week, Open Label, Uncontrolled Study of the Safety and Efficacy of Ferriprox™ (Deferiprone) Oral Solution in Iron Overloaded Pediatric Patients With Transfusion-Dependent Anemia
- The primary objective is to assess the safety of Ferriprox oral solution for the
treatment of iron overload in pediatric patients with transfusion-dependent anemia.
- The secondary objective is to assess the efficacy of Ferriprox oral solution in
reducing iron overload in pediatric patients with transfusion-dependent anemia.
This will be a multi-centre, open label, single treatment, uncontrolled study. A total of 100 iron-overloaded pediatric patients with transfusion-dependent anemia will be enrolled in the study.Eligible patients will receive Ferriprox (deferiprone) oral solution, 100 mg/mL, at a total daily dose of 75 mg/kg body weight or 100 mg/kg body weight, divided in three (3) doses, for 24 weeks. ;
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04423237 -
Risk Factors and Measures to Prevent Liver and Pancreas Complications in Pediatric Patients After HSCT
|
||
Completed |
NCT04614779 -
Long-term Clinical Study of CN128 in Thalassemia Patients
|
Phase 2 | |
Withdrawn |
NCT03800446 -
Validation of a Point-of-care Device Measuring Ferritin With Capillary Blood
|
N/A | |
Not yet recruiting |
NCT02833493 -
Study of MRI Monitoring in Patients With Aplastic Anemia and Low or Int-1 Risk of MDS Complicated With Iron Overload
|
N/A | |
Completed |
NCT02164253 -
Focal Accumulation of Iron in Cerebral Regions in Early ALS (Amyotrophic Lateral Sclerosis) Patients
|
Phase 2 | |
Completed |
NCT00901199 -
Combined Chelation Therapy in Patients With Transfusion Dependent Thalassemia and Iron Overload
|
Phase 2 | |
Completed |
NCT00512226 -
Iron Overload Assesment in Sickle Cell Anemia and Sickle Cell Thalassemia
|
N/A | |
Recruiting |
NCT00378469 -
Study of the Effects of Muscular Activity on Iron Metabolism
|
N/A | |
Completed |
NCT00117507 -
Study for the Treatment of Transfusional Iron Overload in Myelodysplastic Patients
|
Phase 4 | |
Completed |
NCT00138684 -
Cytochrome P450 2E1 and Iron Overload
|
Phase 2 | |
Completed |
NCT03990181 -
Inhibiting Dietary Iron Absorption in Subjects With Hereditary Hemochromatosis by a Natural Polyphenol Supplement
|
N/A | |
Terminated |
NCT02274233 -
Safety and Pharmacokinetic Study of Escalating Doses of SP-420, an Iron Chelator, in Patients With β-Thalassemia
|
Phase 1 | |
Active, not recruiting |
NCT01443195 -
Iron Metabolism in Small Pre Term Newborns
|
N/A | |
Completed |
NCT01546415 -
Safety and Efficacy of Desferasirox in Chinese Patients With Iron Overload and Aplastic Anemia
|
Phase 4 | |
Completed |
NCT01572818 -
Effects of Phlebotomy on Insulin Sensitivity in Insulin Resistance-associated Hepatic Iron Overload Patients
|
N/A | |
Not yet recruiting |
NCT00980421 -
Safety of Various Mode of Delivery of Iron Supplement on Iron Toxicity Markers in Preschool Children
|
Phase 3 | |
Completed |
NCT01047098 -
Effects of Taking Prenatal Vitamin-mineral Supplements During Lactation on Iron Status and Markers of Oxidation
|
N/A | |
Recruiting |
NCT05294471 -
Fully Automated High-Throughput Quantitative MRI of the Liver
|
||
Completed |
NCT03591575 -
Safety and Efficacy of Early Treatment With Deferiprone in Infants and Young Children
|
Phase 4 | |
Active, not recruiting |
NCT00907283 -
Ferrochelating Treatment in Patients Affected by Neurodegeneration With Brain Iron Accumulation (NBIA)
|
Phase 2 |